Join us for our March LIVE webinars on metastatic colorectal cancer & hepatocellular carcinoma. In each broadcast, a pair of experts will speak LIVE on the pressing topics of diagnosis, treatment, and outcome. RSVP today to both!

FDA Approves New Drug Regimen for Acute Lymphoblastic Leukemia

BRIELLE BENYON
Thursday, December 20, 2018
The Food and Drug Administration approved calaspargase pegol-mknl (Asparlas)–an asparagine specific enzyme–as a component of a chemotherapy regimen to treat adult and pediatric patients with acute lymphoblastic leukemia (ALL), according to the agency.

The approval allows a longer interval between doses compared to other pegaspargase products, and was based on a demonstration of the achievement and maintenance of nadir serum asparginase activity above 0.1 U/mL when using when using calaspargase pegol-mknl, 2500 U/m2 via IV every 3 weeks. The drug was evaluated when it was given in combination with a multiagent chemotherapy in 124 patients with B-cell lineage ALL.

The enzyme was initially investigated in the DFCI 11-001, an open-label, randomized, active-controlled, multicenter clinical trial. On the trial, there were 237 children and adolescents with newly diagnosed ALL or lymphoblastic lymphoma–118 were treated with 2,500 U/m2 of calaspargase pegol-mknl given every 3 weeks and 119 were treated with 2,500 U/m2 of pegaspargase given every 2 weeks.

On the calaspargase pegol-mknl arm, 98% of patients with B-cell lineage ALL went into complete remissions, compared to 99% on the pegaspargase arm.

The drug dosing was also studied on the AALL07P4 trial, which included patients with newly diagnosed, high-risk B-precursor ALL. Forty-three patients were given calaspargase pegol-mknl at 2,500 U/m2; 68 patients were given 2,11 U/m2; and 52 patients were given 2,500 U/m2 of pegaspargase as a component of an augmented Berlin-Frankfurt-Münster (BFM) therapy regimen. Median duration of exposure was 7 months.

The induction mortality of patients treated with calaspargase pegol-mknl was 2.8%, and there were no induction deaths in the 52 patients treated with pegaspargase.

Common severe (grade 3 or higher) adverse events that occurred in 10% or more of patients included elevated transaminase (a liver enzyme), increased bilirubin, pancreatitis, and abnormal clotting. The safety profile of the 3-week regimen was similar to the 2-week regimen.

The recommended calaspargase pegol-mknl dose is 2,500 units/m2 intravenously administered at a minimum dosing interval of every 21 days.

This article originally appeared on CURE® as "FDA Approves New Drug Regimen for Acute Lymphoblastic Leukemia."

Talk about this article with nurses and others in the oncology community in the General Discussions Oncology Nursing News discussion group.
External Resources

MJH Associates
American Journal of Managed Care
Cure
MD Magazine
Pharmacy Times
Physicians' Education Resource
Specialty Pharmacy Times
TargetedOnc
OncNurse Resources

Newsroom
Continuing Education
Discussions
Web Exclusives


About Us
Advertise
Advisory Board
Careers
Contact Us
Privacy Policy
Terms & Conditions
Intellisphere, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright OncNursing 2006-2018
Intellisphere, LLC. All Rights Reserved.